Deans' stroke musings: Simple blood test could help predict progression of Parkinson disease

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Wednesday, February 26, 2020

Simple blood test could help predict progression of Parkinson disease

You have a good chance of needing this. What is your doctor's protocol to detect and prevent Parkinsons? Winging it is not the option you want to hear. EXACT PROTOCOLS ARE NEEDED. DEMAND THEM.

Parkinson’s Disease May Have Link to Stroke March 2017

Simple blood test could help predict progression of Parkinson disease

MedicalXpress Breaking News-and-Events | February 11, 2020

In order to provide the best medical care for newly diagnosed Parkinson disease (PD) patients, a method of predicting their cognitive and motor progression, beyond using purely clinical parameters, would have major implications for their management. A novel study published in the Journal of Parkinson's Disease suggests that a blood test for inflammatory and cell senescence biomarkers may be a reliable predictor of cognitive decline, including identifying those who will develop an early dementia and motor progression in PD patients.

"The cumulative incidence of dementia associated with PD is approaching 80%, and individuals with PD are five to six times more likely to develop cognitive impairment than age-matched controls," explained lead investigator Gabriele Saretzki, PhD, Biosciences Institute, and The Ageing Biology Centre at the Campus for Ageing and Vitality of Newcastle University, Newcastle upon Tyne, UK. "PD is known to be associated with inflammation, and we have previously published data demonstrating that a more pro-inflammatory profile in the blood predicts more rapid clinical progression. In this new study, we sought to replicate this finding as well as to study markers of cell senescence (aging), a process that is known to be associated with inflammation and neurodegeneration."

See Also: Comfort and satisfaction with care of home-dwelling dementia patients at the end of life

Investigators examined the association of blood-derived markers with motor and cognitive function over time to discover if this could help to better predict disease progression of newly diagnosed PD patients. More than 150 newly diagnosed PD patients who participated in the Cognitive Impairments in Cohorts with Longitudinal Evaluation-Parkinson's Disease (ICICLE-PD) study and 99 controls underwent physical and cognitive assessments over 36 months of follow-up.

Researchers analyzed whether markers of cellular senescence such as telomere length (TL), p16 and p21 expression, as well as inflammatory markers in blood samples taken close to diagnosis can be predictive of cognitive and motor progression of the disease over the next 36 months. Mean leukocyte TL and the expression of senescence markers p21 and p16 were measured at two time points (baseline and 18 months). Investigators also selected five inflammatory markers from existing baseline data.
The study demonstrated that PD patients had shorter telomeres at baseline and 18 months later compared to age-matched healthy controls. Those PD patients, who had developed dementia after three years, also had significantly shorter telomeres compared to individuals who were dementia-free at this time. Baseline p16 levels were associated with faster rates of motor and cognitive decline over 36 months, while a simple inflammatory summary score at baseline best predicted cognitive score 36 months later in PD patients.
"The development of suitable blood-based biomarkers to predict outcomes is important for neurodegenerative diseases such as PD, which progress over many years," noted Dr. Saretzki. "The markers that we have identified need to be validated in further studies but could ultimately help with planning more targeted management for patients earlier in their disease course. Furthermore, a better understanding of the biological changes that predict disease course has implications for possible future therapies for the disease."
Co-investigator Roger Barker, MBBS, MRCP, Ph.D., Professor of Clinical Neuroscience and Honorary Consultant in Neurology at the University of Cambridge, and at Addenbrooke's Hospital, Department of Clinical Neurosciences, John Van Geest Centre for Brain Repair, University of Cambridge, Cambridge, UK, added: "Being able to reliably predict the clinical path a patient with newly diagnosed PD will follow would greatly help in terms of planning their treatment now and in the way we do trials of disease-modifying interventions in the future. This study provides an example of how this could be done using a simple blood sample."